يعرض 1 - 5 نتائج من 5 نتيجة بحث عن '"Maximino De Guzman Bello"', وقت الاستعلام: 1.02s تنقيح النتائج
  1. 1
    Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

    المؤلفون: Yuriy Vinnyk, Marek Z. Wojtukiewicz, Yaroslav Shparyk, Xavier Pivot, Jin-Hee Ahn, Maximino De Guzman Bello, Sujeong Song, Vladimir Semiglazov, Zbigniew Nowecki, Sanjoy Chatterjee, Igor Bondarenko, Vladimir Moiseyenko, Seock-Ah Im, Ekaterina Trishkina, Jaeyun Lim, Tomasz Sarosiek, Mikhail Dvorkin

    المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(10)

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Cancer Research, medicine.medical_specialty, Cyclophosphamide, Receptor, ErbB-2, medicine.medical_treatment, Breast Neoplasms, Docetaxel, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Double-Blind Method, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Biosimilar Pharmaceuticals, Neoadjuvant therapy, Aged, Epirubicin, Chemotherapy, business.industry, Middle Aged, Neoadjuvant Therapy, Clinical trial, 030104 developmental biology, Fluorouracil, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a617ccd5cfa3ffdde8e7de18d79122c9Test
    https://pubmed.ncbi.nlm.nih.gov/29373094Test


    أضف إلى المفضلة
  2. 2
    A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

    المؤلفون: Tomasz Sarosiek, Yaroslav Shparyk, Vladimir Moiseyenko, Seock Ah Im, Maximino De Guzman Bello, Xavier Pivot, Vladimir Semiglazov, Jae Yun Lim, Marek Z. Wojtukiewicz, M. Dvorkin, J.-H. Ahn, Y. Lee, Igor Bondarenko, Ekaterina Trishkina, Zbigniew Nowecki, Sanjoy Chatterjee

    المصدر: European journal of cancer (Oxford, England : 1990). 93

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Cancer Research, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Breast Neoplasms, Docetaxel, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Breast cancer, Double-Blind Method, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Biosimilar Pharmaceuticals, Cyclophosphamide, Neoadjuvant therapy, Aged, Epirubicin, Chemotherapy, business.industry, Hazard ratio, Middle Aged, medicine.disease, Prognosis, Neoadjuvant Therapy, Survival Rate, 030104 developmental biology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Fluorouracil, business, medicine.drug, Follow-Up Studies

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49516f0b86f6bc234ba48ba45cbbea65Test
    https://pubmed.ncbi.nlm.nih.gov/29680363Test


    أضف إلى المفضلة
  3. 3
    Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial

    المؤلفون: Xiaohui He, Rajendra Singh Arora, Jin Hyoung Kang, Ye Guo, Cheng-Hsu Wang, Myung-Ju Ahn, Ezra E.W. Cohen, Yuan Geng, P. Li, Krishna M. Kamble, Lef Zografos, Qingyuan Zhang, Maximino De Guzman Bello, Ping Zhang Tang, Alaa Kandil, Vijay Kumar, Sung-Bae Kim, Arunee Dechaphunkul, Wei Li, Anthony T.C. Chan

    المصدر: Journal of Clinical Oncology. 37:6024-6024

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Second line treatment, business.industry, Afatinib, Head neck, medicine.disease, Head and neck squamous-cell carcinoma, Internal medicine, medicine, Methotrexate, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::2ecc102f27631264e6ca34d61448d09cTest
    https://doi.org/10.1200/jco.2019.37.15_suppl.6024Test


    أضف إلى المفضلة
  4. 4
    A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer

    المؤلفون: Seock-Ah Im, Maximino De Guzman Bello, Sanjay Chattopadhyay, Jae Yun Lim, Vladimir Semiglazov, Igor Bondarenko, Tomasz Sarosiek, Mikhail Dvorkin, Ekaterina Trishkina, Sujeong Song, Yaroslav Shparyk, Marek Z. Wojtukiewicz, Xavier Pivot, Vladimir Moiseyenko, Jin-Hee Ahn

    المصدر: Journal of Clinical Oncology. 35:509-509

    مصطلحات موضوعية: Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, 030219 obstetrics & reproductive medicine, Cyclophosphamide, business.industry, medicine.medical_treatment, Confidence interval, 03 medical and health sciences, 0302 clinical medicine, Docetaxel, Trastuzumab, 030220 oncology & carcinogenesis, Internal medicine, medicine, Clinical endpoint, business, Neoadjuvant therapy, medicine.drug, Epirubicin

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::289a95b9132c24d0f4ef63153c50028dTest
    https://doi.org/10.1200/jco.2017.35.15_suppl.509Test


    أضف إلى المفضلة
  5. 5
    One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment

    المؤلفون: Vladimir Semiglazov, Maximino De Guzman Bello, Xavier Pivot, S-A. Im, Marek Z. Wojtukiewicz, Jae Yun Lim, Yaroslav Shparyk, L. Younju, Zbigniew Nowecki, Sanjoy Chatterjee, Tomasz Sarosiek, J-H. Ahn, I. Bondarenko, Yuriy Vinnyk, Ekaterina Trishkina, Vladimir Moiseyenko, M. Dvorkin

    المصدر: ResearcherID

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, 030219 obstetrics & reproductive medicine, business.industry, medicine.medical_treatment, Immunogenicity, Biosimilar, Hematology, 03 medical and health sciences, 0302 clinical medicine, Trastuzumab, 030220 oncology & carcinogenesis, Internal medicine, medicine, business, Adjuvant, Early breast cancer, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32710c319c83b36d3955dc96f3e0c284Test
    http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000411324000081&KeyUID=WOS:000411324000081Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث